NASDAQ · Medical - Devices

INGN (INGN) Stock

$5.39 +1.13% NASDAQ: INGN Healthcare

Valuation

MetricValue
Price$5.39
Market Cap$145.93M
P/E Ratio-5.97
P/B Ratio0.83
P/S Ratio0.41
EPS (TTM)$-0.85
52-Week High$9.13
52-Week Low$5.32
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-13.17%
ROA-8.61%
ROCE-13.94%
Gross Margin-8.60%
Operating Margin-8.60%
Net Margin-6.94%
Debt/Equity0.09
Current Ratio3.09

Annual Financials (USD)

Metric20212022202320242025
Revenue$358.0M$377.0M$316.0M$336.0M$349.0M
Operating Profit$9.0M$-85.0M$-109.0M$-43.0M$-30.0M
Net Profit$-6.0M$-84.0M$-102.0M$-36.0M$-23.0M
EPS$-0.28$-3.67$-4.42$-1.52$-0.85
Op Margin2.6%-22.6%-34.6%-12.7%-8.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$490.0M$405.0M$326.0M$296.0M$299.0M
Total Liabilities$119.0M$108.0M$121.0M$122.0M$106.0M
Cash$236.0M$187.0M$125.0M$114.0M$104.0M
Borrowings$27.0M$23.0M$22.0M$19.0M$17.0M

Latest News

Inogen Names Chief Operating Officer MT Newswires · Jul 1, 2026 Inogen Announces the Appointment of Andy Reding as Chief Operating Officer Business Wire · Jul 1, 2026 Here's Why You Should Retain Inogen Stock in Your Portfolio for Now Zacks · Jun 25, 2026 How The Inogen (INGN) Story Is Shifting With New Targets And Execution Questions Simply Wall St. · May 11, 2026 INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves Zacks · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$24.0M$-38.0M$-3.0M$6.0M$-11.0M
Investing Cash Flow$-39.0M$-32.0M$-86.0M$-31.0M$-37.0M
Financing Cash Flow$-1.0M$-1.0M$-1.0M$-1.0M$-4.0M
Net Cash Flow$24.0M$-49.0M$-62.0M$-8.0M$-12.0M
Free Cash Flow$0$-59.0M$-30.0M$-11.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.41
EV / EBITDA-11.05
FCF Yield-6.66%
Quick Ratio2.34
Interest Coverage0.00
Return 1Y-5.66%
Return 3Y-28.80%
Return 5Y-90.46%

Ownership

Insiders Held12.64%
Institutions Held77.54%
Institutions Float Held88.76%
Institutional HolderSharesReport Date
Blackrock Inc.1,647,0842026-03-31
Armistice Capital, LLC1,200,0002026-03-31
Acadian Asset Management. LLC1,083,4832026-03-31
Vanguard Capital Management LLC1,036,7052026-03-31
Ameriprise Financial, Inc.859,5432026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CATX $3.10 +0.00% -2.59 $353.54M 0.00%
EPRX $7.45 +17.51% -5.99 $249.43M 0.00%
HCAT $1.69 -1.17% -0.54 $124.88M 0.00%
HSDT $2.08 -0.48% -1.25 $121.44M 0.00%
NNOX $0.76 -2.81% -1.56 $53.16M 0.00%

About INGN

INGN is led by CEO Kevin R. Smith, employs 766 people, headquartered in US, publicly traded since 2014.

INGN stock trades at $5.39 with a market capitalization of $145.93M. The stock is valued at a price-to-earnings (P/E) ratio of -5.97, price-to-book of 0.83, price-to-sales of 0.41. Over the past 52 weeks the stock has ranged between $5.32 and $9.13, and currently trades 41.0% below its 52-week high.

On profitability, INGN generates a return on equity (ROE) of -13.17%, return on capital employed of -13.94%, an operating margin of -8.60%, a net profit margin of -6.94%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1160.06 +0.01% JNJ Drug Manufacturers - General $275.21 +1.48% ABBV Drug Manufacturers - General $261.70 +0.66% MRK Drug Manufacturers - General $151.64 +1.19% UNH Medical - Healthcare Plans $399.66 +0.85% NVS Drug Manufacturers - General $162.46 +0.75% AZN Drug Manufacturers - General $161.63 -0.52% AMGN Drug Manufacturers - General $442.84 +1.08% TMO Medical - Diagnostics & Research $608.54 +1.34% NVO Biotechnology $46.77 +3.66% ABT Medical - Devices $110.49 +1.43% GILD Drug Manufacturers - General $149.61 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides